Earnings call
Aurobindo Pharma Q2 FY27 earnings call
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The company is planning to expand the Pen-G export market and pursue forward integration; achieving around 12,000 tons by next year would be a great achievement. The company said its China facility had upwards of around 15 products coming out of it. The company reported its highest-ever revenue of 10,263 crores in the second quarter ended September 30, 2026, up 24% year-on-year; operating EBITDA was 2,156 crores, up 28% year-on-year, with a margin of 21%, despite increased input cost and freight rate. Understanding is that the underlying market may be growing at around 20%. US business accounted for almost a 70:30 ratio with the rest of the world a few years back, with the US at 70 and the rest of the world at 30.
The numbers management gave
Results
- The company reported its highest-ever revenue of 10,263 crores in the second quarter ended September 30, 2026, up 24% year-on-year; operating EBITDA was 2,156 crores, up 28% year-on-year, with a margin of 21%, despite increased input cost and freight rate.
Show source
Business performance: We are pleased to report our highest ever revenue for the quarter of 10,263 crores, representing year -on-year growth of 24%.
- Formulation revenue was 9,102 crores in the second quarter ended September 30, 2026, up 24% year-on-year and approximately 89% of consolidated revenue.
Show source
Formulation generated revenue of 9,102 crores, growing 24% year-on-year and accounting for approximately 89% of the consolidated revenue.
- API revenue was 1,162 crores in the second quarter ended September 30, 2026, up 21% year-on-year and approximately 11% of overall revenue.
Show source
API revenue stood at 1,162 crores, growing 21% year-on-year and contributing approximately 11% of the overall revenue.
- The company launched 10 products in the US, filed 7 ANDAs and received 12 final approvals during the second quarter ended September 30, 2026.
Show source
During the quarter, we launched 10 products in the US, filed 7 ANDAs and received 12 final approvals.
- Europe revenue was €288 million in the second quarter ended September 30, 2026, with constant currency growth of 18%.
Show source
Europe delivered revenue of €288 million, with constant currency growth of 18%.
- Gross margin was 61.2% in the second quarter ended September 30, 2026, compared with 59.7% in the corresponding period last year, while contribution stood at 6,280 crores.
Show source
3 Aurobindo Pharma Limited 05 November 2026 Profitability, investments and financial position: Gross margin for the quarter was 61.2% compared to 59.7% in the corresponding period last year, while contribution stood at 6,280 crores.
Show 17 more statements
Results
- R&D expenditure was 376 crores in the second quarter ended September 30, 2026, compared with INR 344 crores in the previous quarter.
Show source
R&D expenditure for the quarter stood at 376 crores against INR 344 crores in previous quarter.
- The company reported revenue from operations of INR 10,263 Cr, EBITDA (Before Forex and Other Income) of 2,156, EBITDA margin of 21.0%, PBT before share of P/L of JV of 1,691, and net profit for the period of 1,124 in the quarter ended September 30, 2026. Aurobindo Pharma Limited's average finance cost was 4.9%, and profit after tax was 1,124 crores in the second quarter ended September 30, 2026.
Show source
Average finance cost of 4.9%, and profit after tax for the quarter was 1,124 crores.
- CDMO opportunities account for probably 10 to 15% of Lannett's total capacity or utilization.
Show source
It’s is probably 10 to 15% of what their total capacity or the utilization.
- Expenses were around 2,150 in the last quarter and around 2,400 in the quarter ended September 30, 2026, reflecting increased freight cost and other costs and Lannett's inclusion; R&D cost increased by about 30 to 40 crores compared with the last quarter.
Show source
This quarter, around 2,400, because there is an increased freight cost and other things, apart from that Lannett has been included.
- The company reported US revenue of INR 4,555 Cr (USD 477 million), an increase of 25% YoY, in the quarter ended September 30, 2026.
Show source
In the US, revenue was 4,555 crores, equivalent to US D 477 million, reflecting growth of 25% year-on-year.
- The company reported Growth Markets revenue of INR 1,026 Cr (USD 107 million), an increase of 16% YoY, in the quarter ended September 30, 2026.
Show source
Revenue from growth market is 1,026 crores or USD 107 million, representing year-on-year growth of 16%.
- The company reported ARV revenue of INR 359 Cr (USD 38 million) in the quarter ended September 30, 2026.
Show source
ARV formulation was $38 million during the quarter, supported by stable volume.
- The company said improved operating leverage across its units improved overall performance.
Show source
But the overall performance has been improved because of the improvement in the operating leverage across the units.
- The company said cost rationalization is reflected in its quarterly results to the extent applicable for the quarter and that it will continue to benefit from the rationalization in different phases.
Show source
It is reflected in our quarterly results to the extent it is applicable for the quarter, and we will continue to benefit from that kind of rationalization.
- Pen-G business is already at a low positive EBITDA, which it expects to increase significantly in the coming quarters, excluding the PLI benefit; the PLI benefit will have an impact on the business once it comes out.
Show source
Already we are in a positive EBITDA, but it’s a very low number, but it is expected to go up in the coming quarters in a significant manner.
- The company launched gAdvair in the middle of the quarter and did not receive the full benefit from the launch in the quarter; higher benefits are expected going forward.
Show source
So, to your question, short answer is, not the full benefit in this quarter that we are discussing.
- Lannett is profitable at its current level, and its first-quarter performance exceeded Aurobindo Pharma's expectations across multiple operating metrics.
Show source
Now, we are highly encouraged with the 1st Quarter performance, which kind of exceeded our expectation across multiple operating metrics.
- Business is growing at a double-digit rate every quarter.
Show source
Yugandhar Puvvala: Yeah, Tarang, the good thing is the business is doing well, and we are growing at a double-digit, every quarter.
- Expenses also increased because of growth taking place across the business. Replaced by a later filing.
Show source
Plus, apart from that, there is a growth taking place everywhere.
Money and capital
- Total capital expenditure was 89 million in the second quarter ended September 30, 2026, including 47 million towards development capabilities and 42 million towards strategic priorities.
Show source
Total capital expenditure stood at 89 million, of which 47 million towards the development capabilities and 42 million towards strategic priorities respectively, thereby supporting our future growth plan.
- The company generated cash flow of USD 146 million during the second quarter ended September 30, 2026, after funding strategic investments and capital allocation initiatives, and closed with a net cash position of USD 189 million.
Show source
We have generated a very strong cash flow of USD 146 million during the quarter after funding strategic investments and capital allocation initiatives, and closed with a net cash position of USD 189 million.
- Routine maintenance or sustainable expenditure is around 50 million per quarter.
Show source
S. Subramanian: If you really see what is going into the regular routine expenditure, I mean, maintenance expenditure or sustainable expenditure, it’s around 50 million per quarter.
What it expects ahead
What management expects
- The company is planning to expand the Pen-G export market and pursue forward integration; achieving around 12,000 tons by next year would be a great achievement.
Show source
Probably, if we are able to achieve around 12,000 tons by next year, I mean, it’s a great achievement.
- The company expects FY28 to be better than FY27 because of various initiatives, the full-year benefit of Lannett, China moving up and Biosimilar; China OpEx loss was around 3 to 4 million in the first half 27 and around a million in the last quarter.
Show source
So, with this we expect FY28 will be better than FY27.
- The company expects expenses to be around 2,450 crores going forward under the current economic scenario.
Show source
So, if you take all this into account, probably going forward with this current economic scenario, we should be around 2,450 crores, type.
- The company may launch one other respiratory product, while another major product may launch beyond 18 months because of the LOE requirement.
Show source
But the other major product may go beyond 18 months, basically because of LOE requirement.
- The company expects to achieve breakeven at its China facility this quarter.
Show source
S. Subramanian: We’ll be achieving the breakeven this quarter , Damayanti.
- The company expects to have its own in-house respiratory product in about the next few months.
Show source
Apart from that, in about next few months, we will also have our own in-house product.
Show 7 more statements
What management expects
- The company expects to have a decent amount of respiratory products in a staggered manner over the next one and a half, two years.
Show source
So, if you see, in a staggered basis for a period of next one and a half, two years, I think we will have a decent amount of product.
- The company expects to sustain double-digit growth while achieving further numbers, supported by growth in its base business ahead of industry growth, exclusivity and late-to-launch generic products, and coming-year and later launches from CuraTeQ and Eugia.
Show source
So, that means, we will be definitely sustaining this double-digit growth, at the same time, achieving further numbers.
- The company anticipates sustained growth in upcoming quarters. Replaced by a later filing.
Show source
And what we anticipate in the upcoming quarters is, this growth will be sustained.
- The company expects the inhalation space to become a major business segment in the future. Replaced by a later filing.
Show source
We believe that this is going to be a major segment that we will be able to exploit in future in terms of business.
- The company said establishing the market and expanding market access and physician adoption for the product will take time. Replaced by a later filing.
Show source
That will take time.
- The company expects respiratory products already launched and its own in-house product to be short-to-medium-term developments. Replaced by a later filing.
Show source
So, these two are in the short-to-medium term, I would say.
- Aurobindo's view is that the biosimilar business will be a durable differentiator and a growing business for generics companies. Replaced by a later filing.
Show source
In the nutshell, what it tells me is the Biosimilar business is going to be a durable differentiator and a growing business for generics companies.
What it is building and selling
Projects and capacity
- The company said its China facility had upwards of around 15 products coming out of it.
Show source
We have got upwards of around 15 products coming out of our China facility.
- The company said Vizag Unit 15, a Europe-focused manufacturing unit, is one of the principal suppliers and contributors to its European sales.
Show source
At the same time, our Vizag Unit 15, which is a Europe-focused manufacturing unit for us, is one of the principal suppliers and the contributors to our European sales.
- The company has the capability to produce 15,000 tons of Pen-G, but has been producing around 10,000 tons because Indian demand is around 9,000 tons; the company is also trying to export and convert Pen-G into other products in the family, including bulk in terms of Formulation, and expects regulatory approvals after filing.
Show source
But however, we have been producing around 10,000 tons only because we have the Indian demand of around 9,000 tons.
- The Lannett facility is underutilized, and Aurobindo Pharma's goal is to utilize it more; doing so requires regulatory filings and products and will take time.
Show source
The Lannett facility is underutilized.
- The company has approval for one inhalation MDI product, preparations for manufacturing are underway, and it has started looking for buyers; at least four other inhalation products are under development.
Show source
So, we’ve already got approval for one product, one of the MDI products.
- The company is back to full production capacities across plants.
Show source
And now we are back to full production capacities across plants.
Show 11 more statements
Demand and pricing
- Understanding is that the underlying market may be growing at around 20%.
Show source
But my understanding is that it may be around 20% possibly.
Segments
- US business accounted for almost a 70:30 ratio with the rest of the world a few years back, with the US at 70 and the rest of the world at 30.
Show source
And coming to the composition of the business, a few years back, we used to be US-heavy, with almost a 70:30 ratio; US is 70 and rest of the world is 30.
- The company had field force in place for the ADQUEY launch in September, before the product was launched in October.
Show source
It has been launched in the month of October.
- The company is not marketing insulin glargine through Lannett and has no plans to launch it anytime soon.
Show source
Swami Iyer: So, Kunal, Aurobindo part of the Lannett, is not marketing the insulin, nor does it have plans of launching it anytime soon.
- Biosimilar products have been commercialized in the UK, and NHS UK acceptance is fairly high, with repeat orders received.
Show source
Yeah, in the UK, these products have been commercialize d. In NHS UK, the acceptance level is fairly high, I would say, because we got some repeat orders as well.
- Aurobindo and CuraTeQ are deliberately selective in choosing their portfolio to advance their interests and support territory players that can market it over a longer life cycle.
Show source
So, our approach at Aurobindo and CuraTeQ is very deliberate, a careful selection of our portfolio, which is chosen to advance our interests and support our territory players who can market this and sustain us in the market over a longer life cycle.
- Aurobindo is open to in-licensing a molecule that falls outside its pipeline when it suits a territory to serve.
Show source
Where a molecule falls outside our pipeline, but, for example, it suits a territory to serve, we are open to in-licensing it.
Deals and partners
- The company has one partnered inhalation asset that was commercially launched in the second quarter ended September 30, 2026, and expects higher volumes and better business as it progresses.
Show source
Swami Iyer: So, partnered inhaler assets, we already have one partnered inhalation asset, which has been commercially launched in this quarter, the quarter that we are discussing.
- The TheraNym product Schedules 1, 2, and 3 signed with MSD are centered around one anchor customer; Aurobindo Pharma plans to expand the business model sometime in the 2030s after building capability and credibility.
Show source
But at this stage, the short answer is the TheraNym product Schedules 1, 2, and 3 that we have signed with MSD is all centered around one anchor customer.
- The company expects the inhalation product being developed with a major pharmaceutical company to be available in the future; the broad potential size of the products under discussion is in billions.
Show source
Swami Iyer: Yeah, I mean, broad number, it will be in billions.
- The company is talking to other partners around the globe to bring additional products into the inhalation space, and discussions with some partners are at a fairly advanced stage.
Show source
And finally, I also want to tell you that we are talking to other partners around the globe for bringing on additional products in the inhalation space.
Risks, rules and outside factors
Outside factors
- The company said increased raw material procurement cost due to the Gulf issue had not yet fully flowed into consumption and would do so in the coming quarter.
Show source
S. Subramanian : So, we had an increase in the raw material procurement cost due to the Gulf issue, but still the overall impact of the cost has not gone into the consumption.
Everything else said on the call
Group structure
- Lanex is not part of Aurobindo Pharma; Lannett is part of Aurobindo Pharma.
Show source
So, Lanex is not part of Aurobindo.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
This transcript does not separate questions and answers, so they are not listed here.
Questions about this call
- When was the Aurobindo Pharma Q2 FY27 earnings call transcript filed?
- Aurobindo Pharma filed the transcript with the exchange on 11 Nov 2026. This page is built from that transcript.
- What does this page list?
- 55 statements from the transcript across 9 topics, 27 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- No. This transcript does not separate the questions from the answers, so they are not listed. The statements by topic still cover what management said.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.